Depression, Anxiety, and Quality of Life in Patients Treated with Single Infusion Tocilizumab for COVID-19: A Follow-up, Controlled Study

BACKGROUND: The inflammatory state that characterizes COVID-19 may contribute to depression, anxiety, other morbidities, and mortality. Interleukin-6 blocker tocilizumab has been used as a treatment modality in COVID-19 as an anti-inflammatory agent. Tocilizumab has also been studied for its potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakravarty, Rahul, Jyani, Gaurav, Paul, Samita, Mohindra, Ritin, Goyal, Manoj, Suri, Vikas, Bhalla, Ashish, Singh, Shubh Mohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896121/
https://www.ncbi.nlm.nih.gov/pubmed/36778618
http://dx.doi.org/10.1177/02537176221140557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896121/
https://www.ncbi.nlm.nih.gov/pubmed/36778618
http://dx.doi.org/10.1177/02537176221140557

Ejemplares similares